2025
Chapter 48 Multicenter considerations
Passarelli R, Sterling J, Singer E, Kim I. Chapter 48 Multicenter considerations. 2025, 245-248. DOI: 10.1016/b978-0-323-90186-4.00029-8.Peer-Reviewed Original Research
2024
Single‑center, retrospective, evaluator‑blinded, pilot and pivotal clinical trials: Assessing the mirCaP Kit (hsv2‑miR‑H9/hsa‑miR‑3659) as a diagnostic marker for prostate cancer in patients with PSA levels in the gray zone
Kim W, Kim K, Kang H, Byun Y, Piao X, Kim Y, Lee S, Yun S, Ha Y, Kim J, Kim I. Single‑center, retrospective, evaluator‑blinded, pilot and pivotal clinical trials: Assessing the mirCaP Kit (hsv2‑miR‑H9/hsa‑miR‑3659) as a diagnostic marker for prostate cancer in patients with PSA levels in the gray zone. Oncology Letters 2024, 29 DOI: 10.3892/ol.2024.14770.Peer-Reviewed Original Research
2023
The disparities in clinical trials addressing urologic conditions among lower-income countries
Choksi A, Hayden C, Rahman S, Lokeshwar S, Kim I. The disparities in clinical trials addressing urologic conditions among lower-income countries. Frontiers In Urology 2023, 2: 1069265. DOI: 10.3389/fruro.2022.1069265.Peer-Reviewed Original ResearchClinical trialsUrologic conditionsGlobal burdenHigh-income countriesLower urinary tract symptomsUrinary tract symptomsUrinary tract infectionUrinary bladder neoplasmsBurden of diseaseOncology clinical trialsActive clinical trialsIncome countriesTract symptomsTract infectionsBladder neoplasmsEvidence-based practiceGenitourinary pathologyNational incidenceDisease 2019Prostatic neoplasmsKidney neoplasmsLow-income countriesNeoplasmsTrialsDisease
2020
Observation with or without late radiotherapy is equivalent to early radiotherapy in high-risk prostate cancer after radical prostatectomy: A SEER-Medicare analysis on trends, survival outcomes, and complications
Kwon Y, Wang W, Srivastava A, Jang T, Singer E, Parikh R, Kim W, Kim I. Observation with or without late radiotherapy is equivalent to early radiotherapy in high-risk prostate cancer after radical prostatectomy: A SEER-Medicare analysis on trends, survival outcomes, and complications. Prostate International 2020, 9: 82-89. PMID: 34386450, PMCID: PMC8322776, DOI: 10.1016/j.prnil.2020.10.002.Peer-Reviewed Original ResearchHigh-risk prostate cancerLate radiotherapyDRT groupProstate cancerSurvival outcomesHigh-risk pathologic featuresMultivariable Cox regression modelsCancer-specific survival outcomesFive-year overallPost-RP radiotherapySEER-Medicare analysisMonths of surgeryWorse survival outcomesKaplan-Meier analysisCox regression modelProportion of menCochran-Armitage trend testEarly radiotherapyPathologic featuresRegression modelsStudy cohortERT groupRadical prostatectomyClinical trialsRadiation toxicity
2019
Couple‐focused interventions for men with localized prostate cancer and their spouses: A randomized clinical trial
Manne S, Kashy D, Zaider T, Kissane D, Lee D, Kim I, Heckman C, Penedo F, Murphy E, Virtue S. Couple‐focused interventions for men with localized prostate cancer and their spouses: A randomized clinical trial. British Journal Of Health Psychology 2019, 24: 396-418. PMID: 30852854, PMCID: PMC8279429, DOI: 10.1111/bjhp.12359.Peer-Reviewed Original ResearchConceptsCouple-focused interventionsRelationship satisfactionPsychological adjustmentCancer-specific distressPsychological adaptationRelationship communicationWellness interventionsStatement of contributionTraditional masculine normsUsual careLocalized prostate cancerRandomized clinical trialsPsychological functioningPsychological treatmentRelationship outcomesAssessment time pointsElevated distressProstate cancerLong relationshipRelationship lengthClinical trialsGeneral healthIntervention benefitsCancer concernsShorter relationships
2018
Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer
Yuh B, Kwon Y, Shinder B, Singer E, Jang T, Kim S, Stein M, Mayer T, Ferrari A, Lee N, Parikh R, Ruel N, Kim W, Horie S, Byun S, Ahlering T, Kim I. Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer. Prostate International 2018, 7: 102-107. PMID: 31485434, PMCID: PMC6713798, DOI: 10.1016/j.prnil.2018.10.002.Peer-Reviewed Original ResearchMetastatic prostate cancerCytoreductive radical prostatectomyPhase 1 studyProstate-specific antigenRadical prostatectomyCytoreductive surgeryProstate cancerSpecific antigenDeath 5 monthsAcute tubular necrosisMajor perioperative complicationsOverall complication rateRapid disease progressionDay of surgerySubset of menPerioperative complicationsPrimary endpointTemporary dialysisComplication rateDisseminated diseaseTubular necrosisMajor complicationsMean ageClinical trialsDisease progression
2016
Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors
Hong J, Kwon Y, Kim I. Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors. Expert Opinion On Drug Metabolism & Toxicology 2016, 13: 183-192. PMID: 27690667, DOI: 10.1080/17425255.2017.1244265.Peer-Reviewed Original ResearchConceptsErectile dysfunctionClinical efficacyEvidence-based clinical efficacyTreatment of EDNon-urological conditionsDrug-related toxicityFirst-line drugsType 5 inhibitorsPhosphodiesterase-5 inhibitorsNew clinical usesChronic administrationBasic science articlesNeuroprotective roleClinical trialsPDE5IsBeneficial effectsClinical usesFurther studiesPharmacodynamicsPharmacokineticsEfficacyInhibitorsImpactful studiesBroad spectrumPDE5i